JP2012236837A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012236837A5 JP2012236837A5 JP2012158751A JP2012158751A JP2012236837A5 JP 2012236837 A5 JP2012236837 A5 JP 2012236837A5 JP 2012158751 A JP2012158751 A JP 2012158751A JP 2012158751 A JP2012158751 A JP 2012158751A JP 2012236837 A5 JP2012236837 A5 JP 2012236837A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- suspension
- polymer
- phthalate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 229920000642 polymer Polymers 0.000 claims 9
- 239000000725 suspension Substances 0.000 claims 9
- 238000000034 method Methods 0.000 claims 7
- 239000002552 dosage form Substances 0.000 claims 5
- 238000000338 in vitro Methods 0.000 claims 5
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 4
- 230000002378 acidificating effect Effects 0.000 claims 4
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 4
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 4
- 239000007962 solid dispersion Substances 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- 238000007922 dissolution test Methods 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 2
- 229940121375 antifungal agent Drugs 0.000 claims 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 2
- 239000006185 dispersion Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 229960004130 itraconazole Drugs 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 238000001694 spray drying Methods 0.000 claims 2
- ARCGXLSVLAOJQL-UHFFFAOYSA-N trimellitic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C(C(O)=O)=C1 ARCGXLSVLAOJQL-UHFFFAOYSA-N 0.000 claims 2
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002301 cellulose acetate Polymers 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000012738 dissolution medium Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 125000005591 trimellitate group Chemical group 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPQ4854 | 1999-12-23 | ||
| AUPQ4854A AUPQ485499A0 (en) | 1999-12-23 | 1999-12-23 | Improved pharmaceutical compositions for poorly soluble drugs |
| AUPQ7450 | 2000-05-12 | ||
| AUPQ7450A AUPQ745000A0 (en) | 2000-05-12 | 2000-05-12 | Improved pharmaceutical compositions for poorly soluble drugs |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001548087A Division JP5159012B2 (ja) | 1999-12-23 | 2000-12-22 | 不良溶解性の薬物に対する改良された医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012236837A JP2012236837A (ja) | 2012-12-06 |
| JP2012236837A5 true JP2012236837A5 (enExample) | 2013-05-30 |
Family
ID=25646230
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001548087A Expired - Fee Related JP5159012B2 (ja) | 1999-12-23 | 2000-12-22 | 不良溶解性の薬物に対する改良された医薬組成物 |
| JP2012158751A Pending JP2012236837A (ja) | 1999-12-23 | 2012-07-17 | 不良溶解性の薬物に対する改良された医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001548087A Expired - Fee Related JP5159012B2 (ja) | 1999-12-23 | 2000-12-22 | 不良溶解性の薬物に対する改良された医薬組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20030086976A1 (enExample) |
| EP (2) | EP1239831B1 (enExample) |
| JP (2) | JP5159012B2 (enExample) |
| AU (2) | AU2331801A (enExample) |
| CA (1) | CA2396380C (enExample) |
| ES (1) | ES2398643T3 (enExample) |
| PT (1) | PT1239831E (enExample) |
| WO (1) | WO2001047492A1 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| PT1239831E (pt) * | 1999-12-23 | 2013-01-23 | Mayne Pharma International Pty Ltd | Composições farmacêuticas melhoradas para fármacos fracamente solúveis |
| GB0012448D0 (en) | 2000-05-24 | 2000-07-12 | Astrazeneca Ab | New process |
| DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| GB0015239D0 (en) * | 2000-06-21 | 2000-08-16 | Biochemie Gmbh | Organic compounds |
| GB0104752D0 (en) * | 2001-02-27 | 2001-04-18 | Astrazeneca Ab | Pharmaceutical compositions |
| WO2003000226A2 (en) * | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions containing polymer and drug assemblies |
| WO2003063822A2 (en) | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| US20040115287A1 (en) * | 2002-12-17 | 2004-06-17 | Lipocine, Inc. | Hydrophobic active agent compositions and methods |
| US20080051411A1 (en) * | 2002-12-17 | 2008-02-28 | Cink Russell D | Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof |
| EP1572190B1 (en) * | 2002-12-17 | 2007-04-18 | Abbott GmbH & Co. KG | Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof |
| US7259186B2 (en) * | 2002-12-17 | 2007-08-21 | Abbott Laboratories | Salts of fenofibric acid and pharmaceutical formulations thereof |
| CL2004001884A1 (es) * | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US20060003002A1 (en) * | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
| US7507823B2 (en) | 2004-05-06 | 2009-03-24 | Bristol-Myers Squibb Company | Process of making aripiprazole particles |
| US20080152714A1 (en) * | 2005-04-08 | 2008-06-26 | Yi Gao | Pharmaceutical Formulations |
| JP2007308480A (ja) * | 2006-04-20 | 2007-11-29 | Shin Etsu Chem Co Ltd | 腸溶性固体分散体を含んでなる固形製剤 |
| US20070275052A1 (en) * | 2006-05-24 | 2007-11-29 | Glenmark Pharmaceuticals Limited | Pharmaceutical compositions containing sterol inhibitors |
| EP2037888A2 (en) * | 2006-06-26 | 2009-03-25 | Mutual Pharmaceutical Company, Inc. | Active agent formulations, methods of making, and methods of use |
| US8946200B2 (en) * | 2006-11-02 | 2015-02-03 | Southwest Research Institute | Pharmaceutically active nanosuspensions |
| CN101600419B (zh) * | 2006-12-22 | 2012-05-09 | 株式会社柳韩洋行 | 含有瑞伐拉赞的固体分散体以及其制备方法 |
| EP2134327A1 (en) * | 2007-03-13 | 2009-12-23 | Sandoz AG | Pharmaceutical compositions of poorly soluble drugs |
| WO2009114365A2 (en) * | 2008-03-13 | 2009-09-17 | Mallinckrodt Inc. | Multi-function, foot-activated controller for imaging system |
| US8404850B2 (en) * | 2008-03-13 | 2013-03-26 | Southwest Research Institute | Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors |
| TWI388324B (zh) * | 2008-04-15 | 2013-03-11 | Schering Corp | 含有泊沙康唑（ｐｏｓａｃｏｎａｚｏｌｅ）之高密度組合物及包含該組合物之調配物 |
| WO2009129301A2 (en) * | 2008-04-15 | 2009-10-22 | Schering Corporation | Oral pharmaceutical compositions in a molecular solid dispersion |
| US8722706B2 (en) * | 2008-08-15 | 2014-05-13 | Southwest Research Institute | Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts |
| US8309134B2 (en) * | 2008-10-03 | 2012-11-13 | Southwest Research Institute | Modified calcium phosphate nanoparticle formation |
| US20100159010A1 (en) * | 2008-12-24 | 2010-06-24 | Mutual Pharmaceutical Company, Inc. | Active Agent Formulations, Methods of Making, and Methods of Use |
| US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
| JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| US9028873B2 (en) * | 2010-02-08 | 2015-05-12 | Southwest Research Institute | Nanoparticles for drug delivery to the central nervous system |
| US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
| EP2782557B1 (en) * | 2011-11-23 | 2018-09-12 | Array Biopharma, Inc. | Pharmaceutical formulations |
| US9650851B2 (en) | 2012-06-18 | 2017-05-16 | Schlumberger Technology Corporation | Autonomous untethered well object |
| AU2013278001A1 (en) | 2012-06-21 | 2015-01-22 | Mayne Pharma International Pty. Ltd. | Itraconazole compositions and dosage forms, and methods of using the same |
| US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
| EP2837391B1 (en) | 2013-08-12 | 2017-05-10 | Shin-Etsu Chemical Co., Ltd. | Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate |
| CN104644557B (zh) * | 2013-11-22 | 2017-10-31 | 上海宣泰医药科技有限公司 | 卟啉铁固体分散体及其制备方法 |
| US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
| WO2016033556A1 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS |
| WO2016198983A1 (en) | 2015-06-09 | 2016-12-15 | Bend Research Inc. | Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules |
| US20160361322A1 (en) | 2015-06-15 | 2016-12-15 | Lipocine Inc. | Composition and method for oral delivery of androgen prodrugs |
| US20180147215A1 (en) | 2016-11-28 | 2018-05-31 | Lipocine Inc. | Oral testosterone undecanoate therapy |
| CA3050696A1 (en) * | 2017-01-20 | 2018-07-26 | Constellation Pharmaceuticals, Inc. | Solid dispersions of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide |
| US11390613B2 (en) | 2017-08-20 | 2022-07-19 | University Of Connecticut | Azole analogues and methods of use thereof |
| AU2019308326B2 (en) | 2018-07-20 | 2025-07-31 | Lipocine Inc. | Liver disease |
| US10702520B1 (en) | 2019-01-29 | 2020-07-07 | Slayback Pharma Llc | Pharmaceutical compositions of posaconazole |
| US11318107B2 (en) | 2019-02-22 | 2022-05-03 | Avior, Inc. | Pharmaceutical active-containing film delivery device for oral transmucosal administration |
| US12435067B2 (en) | 2019-08-09 | 2025-10-07 | University Of Connecticut | Truncated itraconazole analogues and methods of use thereof |
| PH12022550492A1 (en) * | 2019-08-28 | 2022-12-19 | Shenzhen Chipscreen Biosciences Co Ltd | Chidamide pharmaceutical composition, preparation method therefor and application thereof |
| US20210346506A1 (en) | 2020-05-07 | 2021-11-11 | Guibai Liang | Prodrug of itraconazole and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02167219A (ja) * | 1988-12-20 | 1990-06-27 | Fujisawa Pharmaceut Co Ltd | 固体分散体の製造方法 |
| JP3110794B2 (ja) | 1991-06-05 | 2000-11-20 | ユーシービージャパン株式会社 | １，４−ジヒドロピリジン誘導体を含有する製剤 |
| US5340591A (en) * | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| PH30929A (en) * | 1992-09-03 | 1997-12-23 | Janssen Pharmaceutica Nv | Beads having a core coated with an antifungal and a polymer. |
| PT784974E (pt) | 1995-07-26 | 2003-09-30 | Kyowa Hakko Kogyo Kk | Preparacao de derivados de xantina numa dispersao solida |
| KR19990044257A (ko) * | 1996-05-20 | 1999-06-25 | 디르크 반테 | 생체이용율이 개선된 항진균성 조성물 |
| EP0954288B1 (en) * | 1996-06-28 | 2004-08-11 | Schering Corporation | Solid solution of an antifungal agent with enhanced bioavailability |
| ATE364374T1 (de) * | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| AU1511399A (en) * | 1997-12-31 | 1999-07-19 | Choongwae Pharma Corporation | Method and composition of an oral preparation of itraconazole |
| KR100336090B1 (ko) * | 1998-06-27 | 2002-05-27 | 윤승원 | 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제 |
| DE19843904A1 (de) * | 1998-09-24 | 2000-03-30 | Basf Ag | Feste Dosierungsform mit polymerem Bindemittel |
| JP2002534371A (ja) * | 1999-01-06 | 2002-10-15 | コリア リサーチ インスティテュート オブ ケミカル テクノロジー | 水不溶性薬物を含む医薬的活性成分の製造方法及びそれを含む経口投与用医薬組成物 |
| ES2307482T3 (es) * | 1999-02-10 | 2008-12-01 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas. |
| PT1239831E (pt) * | 1999-12-23 | 2013-01-23 | Mayne Pharma International Pty Ltd | Composições farmacêuticas melhoradas para fármacos fracamente solúveis |
-
2000
- 2000-12-22 PT PT986890T patent/PT1239831E/pt unknown
- 2000-12-22 WO PCT/AU2000/001592 patent/WO2001047492A1/en not_active Ceased
- 2000-12-22 CA CA2396380A patent/CA2396380C/en not_active Expired - Lifetime
- 2000-12-22 ES ES00986890T patent/ES2398643T3/es not_active Expired - Lifetime
- 2000-12-22 EP EP00986890A patent/EP1239831B1/en not_active Expired - Lifetime
- 2000-12-22 AU AU23318/01A patent/AU2331801A/en not_active Abandoned
- 2000-12-22 JP JP2001548087A patent/JP5159012B2/ja not_active Expired - Fee Related
- 2000-12-22 EP EP20110187961 patent/EP2415462A1/en not_active Withdrawn
- 2000-12-22 AU AU72529/00A patent/AU782469B2/en not_active Expired
-
2002
- 2002-06-21 US US10/175,883 patent/US20030086976A1/en not_active Abandoned
-
2003
- 2003-06-16 US US10/461,503 patent/US6881745B2/en not_active Expired - Lifetime
-
2007
- 2007-06-15 US US11/763,578 patent/US8771739B2/en not_active Expired - Lifetime
-
2012
- 2012-07-17 JP JP2012158751A patent/JP2012236837A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012236837A5 (enExample) | ||
| JP2017536398A5 (enExample) | ||
| JP2009502969A5 (enExample) | ||
| KR20160098508A (ko) | 경구용 약학 조성물 | |
| JP2009525300A5 (enExample) | ||
| RU2014152031A (ru) | Составы твердых дозированных лекарственных форм антагониста орексинового рецептора | |
| JP2009537611A5 (ja) | リポ酸のペレット | |
| JP2013103899A (ja) | 難溶性薬物の新規な固体分散体 | |
| CN104922086A (zh) | 一种质子泵抑制剂肠溶片的制备方法 | |
| CN104540499A (zh) | 含有药物的中空颗粒 | |
| RU2017142563A (ru) | Твердые дисперсии q10 | |
| JP2019509345A5 (enExample) | ||
| RU2011135837A (ru) | Пероральная основа в виде пленки | |
| JP2015510935A5 (enExample) | ||
| WO2011098194A3 (en) | Pharmaceutical mini-tablets for sustained release of flecainide acetate | |
| Obara et al. | Properties and applications of hypromellose acetate succinate (HPMCAS) for solubility enhancement using melt extrusion | |
| CN104188935B (zh) | 一种兰索拉唑肠溶片及其制备方法 | |
| JP2016501944A (ja) | 複合体形成用組成物、そこから形成された複合体、及びそれを含む経口摂取用組成物 | |
| CN103520169A (zh) | 米氮平片及其制备方法 | |
| Cheng et al. | Aqueous polymer dispersion coating used for osmotic pump tablets: membrane property investigation and IVIVC evaluation | |
| CN101933913A (zh) | 一种盐酸右哌甲酯双释放制剂及其制备方法 | |
| CN104997757A (zh) | 雷贝拉唑钠肠溶微丸胶囊及其制备方法 | |
| WO2015085739A1 (zh) | 一种多层固体药物剂型 | |
| CN101015537A (zh) | 铁叶绿酸钠－乙基纤维素微胶囊的制备方法 | |
| CN102552163B (zh) | 一种酒石酸美托洛尔缓释微丸及其制备方法 |